ArticleRegenerative engineering and translational medicine2020
The Challenge of Variability in Chimeric Antigen Receptor T cell Manufacturing.
Article in Regenerative engineering and translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Generation of therapeutic T cells from human induced pluripotent stem cells.Inflammation and regeneration · 2026Review
- Strategies to eliminate native T cell receptors for adoptive T cell therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- Allogeneic CRISPR-Engineered CAR-T Cells Drive Potent Antitumor Activity in Solid Tumors.bioRxiv : the preprint server for biology · 2026Article
- Determinants of Chimeric Antigen Receptor (CAR) T Cell Success: In Vitro and In Vivo Preclinical Assessment.Cancers · 2026Review
- Label-free metabolic imaging monitors the fitness of chimeric antigen receptor T cells.Nature biomedical engineering · 2026Article
- Two-stage inertial microfluidics enrichment of activated T-cells towards a bead-less chimeric antigen receptor manufacturing protocol.Medical oncology (Northwood, London, England) · 2026Article
- Nanomedicine-Empowered CAR-T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy.International journal of nanomedicine · 2026Review
- Advancing CAR-T cell therapy: Insights into patient biology, leukapheresis, and cryopreservation.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Development of production methodologies for scFv-Fc conjugated critical reagents to support CAR-T clinical programs.Bioanalysis · 2025Article
- Cell trajectory modulation: rapid microfluidic biophysical profiling of CAR T cell functional phenotypes.Nature communications · 2025Article
- Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility.Journal of translational medicine · 2025Article
- Taming Variability in T-Cell Mechanosensing.Cells · 2025Article
- Leveraging Single-Cell Multi-Omics to Decode Tumor Microenvironment Diversity and Therapeutic Resistance.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer.Journal of translational medicine · 2024Article
- Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study.Journal for immunotherapy of cancer · 2023Article
- Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation.Frontiers in immunology · 2023Review
- Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.Blood cancer discovery · 2021Review
- Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives.Viruses · 2021Review
- Article
- Clinical development of natural killer cells expressing chimeric antigen receptors.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Autologous Chimeric Antigen Receptor (CAR) T cell manufacturing involves the modification and expansion of T cells obtained by apheresis collection from a patient. The mechanism of apheresis collection and the specific clinical features seen in these patients combine to generate apheresis products with high variability of content. Manufacturers often attempt to minimize this variability such that processes can be standardize in accordance with Good Manufacturing Practices (GMP). Such standardization improves efficiency and helps to ensure robustness of the overall process. Apheresis product variability can negatively impact T cell manufacturing success. Patient and collection driven variability often leads to non-T cells entering the apheresis product. Many of these cells can directly or indirectly impair T cell activation and expansion, decreasing the manufacturing success rate. Therefore, patient driven variability observed in apheresis products, must be mitigated through downstream processing. T cell enrichment is one step in the manufacturing cycle that can reduce process variability by generating more uniform downstream material. However, current T cell enrichment methods have limitations. Much of this type of variability can be avoided by collecting patients earlier in their disease or treatment course, this is not current, widespread or standard practice. While variability poses challenges to successful CAR T cell manufacturing and mitigation strategies can be successful, more work is needed in this area.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.